Clinical Trial Detail

NCT ID NCT02516241
Title Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

urethra transitional cell carcinoma

transitional cell carcinoma

Therapies

Durvalumab + Tremelimumab

Carboplatin + Cisplatin + Gemcitabine

Durvalumab

Age Groups: adult senior

No variant requirements are available.